Out now in Nature Metabolism! 🖥️🧬 An Open Targets project has identified a set of plasma proteins that could be used to diagnose and monitor patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) www.nature.com/articles/s42...

VIDRA is out now on medRxiv! Variant-Informed Dose-Response Analysis (VIDRA) is a computational framework which infers genetic dose-response relationships by integrating trait-associated variants across a spectrum of allele frequencies and functional consequences. www.medrxiv.org/content/10.6...

“The scale at which we’re doing things, and in such an unbiased way, means that anything could come out of it. You have to be open to a new theory or something completely out of the ordinary happening.” Lewis Evans is @sangerinstitute.bsky.social Senior Staff Scientist and Open Targets project lead

The Open Targets Platform 26.06 release is out now! ✋ 🔴 Find out about all the updates on the blog: blog.opentargets.org/open-targets...

“There isn’t anywhere else in the world where you’ve got genomics, computational, clinical, biological, and pharmaceutical expertise all in one group or consortium.” @mhaniffa.bsky.social discusses her experience working with partners across industry and academia as part of her Open Targets project

How do you ensure the stability of a platform with millions of data points updated every release? You start testing patterns In the last release of the Open Targets Platform, we implemented automated end-to-end testing into our development workflow 🧬🖥️ blog.opentargets.org/end-to-end-t...

New study into Crohn’s disease helps explain why gut inflammation persists, and could help unlock more targeted treatments for patients. Researchers analysed millions of gut cells, uncovering lasting molecular changes and key inflammatory immune cells. 👇 www.sanger.ac.uk/news_item/ce...

Out now in Nature Genetics! The largest single-cell RNA sequencing dataset of terminal ileal biopsies profiles 1.1 million cells from over 100 Crohn’s disease patients and over 200 healthy controls. Crohn’s disease is a type of inflammatory bowel disease (IBD) www.nature.com/articles/s41...

“Open Targets has had the single biggest impact in integrating the @sangerinstitute.bsky.social and @ebi.embl.org science, above and beyond any other initiative I’ve seen in that time." 🤝

Out now in Nature! Genetic analysis of the largest single-cell dataset of Inflammatory Bowel Disease (IBD)-relevant tissues nominates effector genes and cell types at over half of known IBD loci, including 74 for which this is the first candidate effector gene 🖥️🧬 www.nature.com/articles/s41...

We're at #ESHG2026! Come say hello and find out about current Open Targets projects. See you there!

Excited to release #OpenSplice - the impact of >500,000 mutations on the alternative splicing of 600 human exons www.biorxiv.org/content/10.6... Led by @gioia-quarantani.bsky.social + funded by @opentargets.org ‬ @sangerinstitute.bsky.social @crg.eu #cshlsymp26 #RNA2026 @rnasociety.bsky.social

Introducing OpenSplice, an atlas of splice-altering variants and the largest systematic analysis of splicing regulatory variants OpenSplice quantifies the impact of 590,000+ variants on the splicing of 608 alternatively spliced exons, and is out now on bioRxiv 🧬🖥️ www.biorxiv.org/content/10.6...

1\ Excited to finally share some of my PhD work: OpenSplice! We measured how >590,000 mutations affect exon inclusion across 600 human exons, creating a resource to study splicing regulation, benchmark variant effect predictors, and support variant interpretation.

Design is a team sport. Galabina Yordanova and Adedoyin Okunade share how they crafted an intuitive experience for the Perturbation Catalogue through user research and iterative design. blog.opentargets.org/designing-th...

GWAS discovery is far from saturation. We need more GWAS, and more diverse GWAS 🧬🖥️

How do you present complex information in an easily understandable and visually appealing way? Our web developer Graham McNeill walks you through our design process for visualising locus-to-gene scores in the Platform: blog.opentargets.org/design-proce...

"Beyond the technical aspects of large-scale data analysis, the internship gave me a clearer view of how deep biological knowledge and genetic evidence can be combined to support target discovery and safety assessment." 🖥️🧬 blog.opentargets.org/from-genetic...

Want to maximise your chance of clinical success? Gene-disease associations with: 1️⃣ Genetic support from protein-altering variants 2️⃣ Intermediate pleiotropy are 10 times more likely to result in approved medicines, balancing impactful genetic variation with genetically informed safety liability

How can you compare cells across conditions? We chat to Marie Moullet about Tripso, a self-supervised transformer model she co-developed for single cell data analyses going beyond canonical cell type markers and annotations to understand cell states blog.opentargets.org/how-the-lotf...

Our findings from the largest systematic analysis of complex trait associations is out now on bioRxiv! 🧬🖥️ www.biorxiv.org/content/10.6...

🧬 New preprint: "The Human Pleiotropic Map of GWAS Associations and Therapeutic Implications" Why do some genetically supported drug targets succeed in the clinic while others fail? Across 100,526 GWAS, the same evidence flags constrained gene functions rarely safe to modulate.

What a conversation! 🙌 Thank you to everyone who joined "Closed Licences, Closed Doors" with @knowledgerights21.org Do restrictive licences protect your research from AI, or just limit its impact? Couldn't make it? Watch the recording 👇 youtu.be/BprlLw6CRyI #OpenScience #AcademicSky 🧪

📣Tomorrow: Closed Licences, Closed Doors webinar! Join us and @knowledgerights21.org to find out about open licensing, AI, and the future of research impact! 🗓️ 14 April | ⏰ 10:00 BST/11:00 CEST There's still time to register 👉 embl-org.zoom.us/meeting/regi... #OpenScience #AcademicSky 🧪

🧬🖥️ Introducing TRIPSO: a transformer network to help interpret single cell data analyses by learning multiple predefined or data-driven gene programme-specific embeddings Tripso was developed by a team across the Lotfollahi, Haniffa, Gottgens and Vento labs www.biorxiv.org/content/10.6...

The reveal is here! Meet your experts: 🎤 Presentations: Dr. David Hulcoop @opentargets.org Dr. Benjamin White @knowledgerights21.org Dr. Summer Rosonovski #EuropePMC 💬 Panel: Melissa Harrison #EuropePMC @ebi.embl.org Dr. Kiera McNeice Research Transparency Manager* Dr. Bastian Drees @embl.org

The Open Targets Platform spring 🌼 release is out — and this one marks the beginning of something we've been building towards for a while.

The Open Targets Platform spring (26.03) release is out now! 🌸 Find all the details of the updates on the blog: blog.opentargets.org/open-targets...

Closed licences, closed doors. We're hosting a webinar with @kr21.bsky.social exploring how licensing shapes real-world research impact, from @opentargets.org to pandemic response. Speaker panel reveal soon 👀 🗓️ 14 April ⏰ 10:00 BST 🔗 embl-org.zoom.us/meeting/regi... #OpenScience #AcademicSky 🧪

Introducing PerturbGen: a generative AI foundation model that predicts how genetic perturbations affect cellular trajectories www.biorxiv.org/content/10.6...

Out now on bioRxiv! 🧬🖥️ Dewi Moonen, @anniquec.bsky.social and a team led by Lars Steinmetz and Daniel Schraivogel at EMBL have mapped the downstream regulatory networks of thousands of immune disease-relevant variants in CD4+ T cells www.biorxiv.org/content/10.6...

Finally I can properly explore the mcp-ui pattern. Pretty interesting how the development of new components (especially complex ones) will change dramatically in how data is loaded into them. Exiting times🔥 building a demo using @opentargets.org components. Ref: mcpui.dev

What does game theory have to do with gene predictions? Irene Lopez explains how we apply Shapley value-based explanations for Locus-to-Gene scores in the Open Targets Platform, addressing a common concern of machine learning models: explainability 🧬🖥️ blog.opentargets.org/how-we-impro...

🧬🖥️ Our latest publication reveals a shift in strategies to discover novel drug targets over the past 20 years: after 2015, biomedical evidence supporting a target-disease indication increasingly appears before the approval year www.nature.com/articles/s41...

Open Targets Platform data is now available on @amazonwebservices.bsky.social through the Open Data Program! registry.opendata.aws/opentargets/

🔬New Perturbation Catalogue update! With a redesigned interface, richer datasets and powerful analysis workflows, it’s now easier than ever to explore genetic perturbation data. www.ebi.ac.uk/perturbation... #Bioinformatics #FunctionalGenomics @training.ebi.embl.org @opentargets.org

The Perturbation Catalogue is live! 🧬🔎🖥️ It aims to bring genetic perturbation data into one curated, harmonised, and discoverable platform. Take a look! www.ebi.ac.uk/perturbation...

🧬🖥️ "This integration is a great example of bringing leading AI to platforms and data that are already widely used across the industry.” — Jonah Cool, Head of Life Sciences Partnerships, Anthropic Find out more about the Open Targets Platform MCP server: blog.opentargets.org/official-ope...

The needle in the haystack problem: spotting novel drug targets among redundant evidence. Our solution? A time-series novelty metric for Open Targets Platform associations. Thanks to Coté Falaguera & @opentargets.org partners for making this happen.

Out now in Nature Communications! 🧬🖥️ An Open Targets team developed a metric for the novelty of a target in the context of a disease, according to current available knowledge. This allows drug discovery scientists to easily identify potentially novel targets www.nature.com/articles/s41...

Out now! 🧬 Loss of CHD1 and MAP3K7 creates an acquired cancer vulnerability, highlighting these genes as potential biomarkers of immune checkpoint blockade response Find out more: www.cell.com/cell-reports...

New biomarkers for cancer immunotherapy have been identified. 🔎 Researchers found that loss of two genes, CHD1 and MAP3K7, makes tumours more likely to respond to immunotherapy. The findings could help support more personalised cancer treatment 👇 bit.ly/4sMBTq2

We're recruiting 3 roles through @sangerinstitute.bsky.social 👩‍🔬🧬💻 NEW: ➡ Postdoc with @carlanderson.bsky.social ➡ Technical Specialist with @bayraktarlab.bsky.social ALSO: ➡ (Senior) Postdoc in Mo Lotfollahi’s lab More information in the thread See all available jobs: opentargets.org/jobs

🚀 Announcing the Official @opentargets.org MCP! We've partnered with @anthropic.com to give AI seamless access to high-quality genetic and target-discovery data. Open for the entire community to accelerate therapeutic development. Read more at blog.opentargets.org/official-ope...

Introducing the official Open Targets Platform Model Context Protocol 🧬🖥️ In partnership with @anthropic.com, we’ve created an MCP server making Open Targets Platform data accessible to AI-powered tools and agents Try it out and watch out for future releases: mcp.platform.opentargets.org/mcp

The Wellcome Genome Campus lit up for the holidays ✨ 📸 Helena Cornu

NEW: NLP data scientists/scientific data engineers at @ebi.embl.org Develop a comprehensive open source side effect resource and standardised AI/ML training sets to improve early identification of safety liabilities Apply by 11 January embl.wd103.myworkdayjobs.com/en-US/EMBL/j...

Open Targets Platform 25.12 is out now! Thanks to a GWAS Catalog update including 3 major studies using UK Biobank data, we now have over 1.4 million GWAS credible sets in the Platform. Discover the data, feature, and technical updates in this release: blog.opentargets.org/open-targets... 🧬🖥️

NEW: multiple (senior) postdoctoral fellow roles in Mo Lotfollahi's group at @sangerinstitute.bsky.social There are many research focus areas available, including Open Targets translational AI projects Apply now: sanger.wd103.myworkdayjobs.com/en-US/Wellco...

#OnThisDay 10 years ago, we launched the Open Targets Platform! 🎂 🧬🖥️